COVID-19: What’s NMR Got to Do with it?
We are living through a public health crisis the likes of which has not been seen for generations. But we go into this crisis with one key advantage compared to previous generations - our scientific knowledge and capabilities are a major weapon against the virus, and we find ourselves in a race against time to develop effective therapies and preventative treatments. NMR is a key technique that forms a part of the backbone of analytical chemistry which so underpins much of drug discovery, development and manufacturing. This talk highlights the importance of NMR in this process, with particular reference to COVID-19. It focuses mainly on the impact of using NMR for the quality control and release of existing drug molecules which are in shortage for one reason or another due to the pandemic, and on the solutions which can assist in this process. The talk will be aimed at both spectroscopists and non-NMR experts alike.
THURSDAY, August 27, 2021
11:00AM EST | 05:00PM CET
Who Should Attend
This webinar will be of interest to those looking to extend and improve their analytical capabilities, heads of analytical and chemical R&D, QC and manufacturing, laboratory managers and expert users of complementary technologies. It is especially dedicated to producers of APIs such as Remdesivir, Dexamethasone, Ribavirin, Midazolam, Hydroxychloroquine, Rocuronium Bromide and Azithromycin.
Speakers
Gary Sharman, PhD
Senior Scientific Director
Gary studied Natural sciences at the University of Cambridge before completing a PhD with prof Dudley Williams on structural and mechanistic studies by NMR and MS. He spent 20 years in the pharmaceutical industry, working in analytical chemistry at AstraZeneca and Eli Lilly, where he developed a particular interest in data flows and visualisations. He moved to Mestrelab in 2020, where his role centres around automation, data processing and customisation.
Anna Codina, Ph.D.
Senior Director Strategy and Business Development, SciY
Anna has a degree in Chemistry and a Ph.D. in Protein NMR from the University of Barcelona, Spain. She undertook her post-doc in protein NMR at the MRC Laboratory of Molecular Biology in Cambridge, UK, and following that worked in the Analytical R&D department of Pfizer for seven years, becoming proficient in low level impurity structure elucidation, reaction monitoring, qNMR and the preparation of regulatory documentation. She received a Pfizer Worldwide Achievement Award for the implementation of reaction monitoring by NMR in an open access environment.
She joined Bruker in 2011 and had different roles since including Material Characterisation Laboratory Manager, Product Portfolio Manager and for several years was in charge of driving the Biopharmaceutical business at Bruker BioSpin. Anna recently moved to SciY as Senior Director of Strategy and Business Development.